OPM Biosciences
OPM Biosciences (奥浦迈) is a Shanghai-based, publicly listed (SSE 688293) cell culture media developer and end-to-end CDMO serving biologics developers in China. Founded in 2013, it employs 251-500 staff and recently expanded into preclinical services via its PharmaLegacy acquisition.
- Company typePrivate
- Founded2013
- HeadquartersShanghai, China
- Headcount251–500
- GTM typeB2B
- OfferingServices
OPM Biosciences firmographics
Firmographics- Name
- OPM Biosciences
- Website
- https://opmbiosciences.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- OPM Biosciences (奥浦迈) is a Shanghai-based, publicly listed (SSE 688293) cell culture media developer and end-to-end CDMO serving biologics developers in China. Founded in 2013, it employs 251-500 staff and recently expanded into preclinical services via its PharmaLegacy acquisition.
- Ownership category
- akta.pro rank
OPM Biosciences industry classification
Industry- Product category
- Biopharmaceutical CDMO Services
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where OPM Biosciences is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Markets served
OPM Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure
OPM Biosciences product offering
Product offeringCore offering
OPM Biosciences develops and manufactures cell culture media products and delivers comprehensive Contract Development and Manufacturing Organization (CDMO) services for biopharmaceutical companies. The company provides end-to-end solutions spanning cell line development, process development, and large-scale manufacturing of biologics, along with the upstream cell culture media consumed in those processes.
Differentiator
Problem solved
Functional benefit
Products and services
- Cell Culture Media (细胞培养基) Manufactured cell culture media products supplied to biopharmaceutical companies for use in upstream biologics production processes such as monoclonal antibody, vaccine, and recombinant protein manufacturing.
- End-to-End CDMO Services Contract development and manufacturing organization services for biopharmaceutical clients, covering the full lifecycle from cell line construction and process development through clinical and commercial-scale biologics manufacturing.
Companies that use OPM Biosciences
Customer profileIdeal customer profiles1 record
OPM Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
OPM Biosciences competitors and assessment
Company assessmentBroad incumbents
- Cytiva (Danaher): Supplies cell culture media, bioreactors, and bioprocessing consumables globally, overlapping with OPM's cell culture media product line as a much larger incumbent.
- Thermo Fisher Scientific (Patheon/Bioservices): Diversified life sciences giant providing both bioprocessing media and CDMO services, comparable to OPM's media-plus-CDMO model across a much broader portfolio.
- MilliporeSigma (Merck KGaA Life Science): Major supplier of cell culture media and bioprocessing solutions with strong CDMO capability via M Lab and BioReliance — a global incumbent competing head-on with OPM's media franchise.
Direct peers
- WuXi Biologics: Global-leading biologics CDMO offering end-to-end development and manufacturing services, directly competing with OPM's CDMO business for Chinese and international biopharma clients.
- Lonza Group: World's largest biologics CDMO with comprehensive cell culture media and manufacturing services across mammalian, microbial, and cell/gene therapy modalities — directly comparable to OPM's integrated offering.
- Samsung Biologics: Large-scale biologics CDMO providing mammalian cell culture manufacturing and integrated services, competing for similar global biopharma outsourcing contracts as OPM.
- GenScript ProBio: China-based CDMO offering gene synthesis, cell therapy, and biologics manufacturing services, directly competing with OPM for Chinese biopharmaceutical customers.
- Pharmaron: Integrated CRO/CDMO with strong China presence offering drug discovery through manufacturing — comparable scope to OPM's end-to-end model post-PharmaLegacy acquisition.
Emerging players
- Bio-Techne: Specialized in cell culture reagents, media, and bioprocessing products used alongside CDMO workflows — overlapping with OPM's cell culture media business as an emerging specialized competitor.
Regional players
- Shanghai STAR Biopharma (Novoprotein): China-based cell culture media and recombinant protein supplier serving domestic biopharma manufacturers — a regional competitor in OPM's core media segment.
Market position
Customer concentration
OPM Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
OPM Biosciences leadership team
Management profileNumber of profiles
Profiles1 record
OPM Biosciences funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OPM Biosciences M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OPM Biosciences
What does OPM Biosciences do?
OPM Biosciences develops and manufactures cell culture media products and delivers comprehensive Contract Development and Manufacturing Organization (CDMO) services for biopharmaceutical companies. The company provides end-to-end solutions spanning cell line development, process development, and large-scale manufacturing of biologics, along with the upstream cell culture media consumed in those processes.
Is OPM Biosciences a public or private company?
OPM Biosciences is a private company. It is classified as public and is currently operating.
When was OPM Biosciences founded?
OPM Biosciences was founded in 2013. It employs 251 to 500 people.
Where is OPM Biosciences based?
OPM Biosciences is headquartered in Shanghai, China, in the Asia region.
Who are OPM Biosciences's main competitors?
Broad incumbents on record are Cytiva (Danaher), Thermo Fisher Scientific (Patheon/Bioservices) and MilliporeSigma (Merck KGaA Life Science). Direct peers are WuXi Biologics, Lonza Group, Samsung Biologics, GenScript ProBio and Pharmaron. Bio-Techne is listed as an emerging player. Shanghai STAR Biopharma (Novoprotein) is listed as a regional player.
Does OPM Biosciences have an API?
No public API is recorded for OPM Biosciences.
What industry is OPM Biosciences in?
OPM Biosciences's product category is Biopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325414 and its SIC code is 8731.